Weight Loss Medication Options: Efficacy and Risks Compared

Weight Regain Is the Rule, Not the Exception

Clinical trials consistently show that most people who lose weight through diet and exercise alone regain it within 3–5 years. The biological mechanisms are formidable: after weight loss, circulating levels of the appetite-stimulating hormone ghrelin increase and leptin decreases, creating a persistent biological drive to regain lost weight. This physiology — not willpower — explains why pharmacological support has become a recognized pillar of obesity medicine. The FDA has approved six drugs (or drug combinations) for long-term weight management since 2012.

Phentermine/Topiramate Extended-Release

The combination of phentermine (a sympathomimetic norepinephrine-releasing agent) with extended-release topiramate (an anticonvulsant that reduces appetite through multiple mechanisms including GABA-A potentiation) was approved as Qsymia in July 2012. In the EQUIP trial, the highest dose (phentermine 15 mg/topiramate 92 mg) produced a mean weight loss of 10.9% of baseline body weight at 56 weeks, versus 1.6% for placebo — a net loss of 9.3 percentage points. In the CONQUER trial (overweight adults with comorbidities), the high-dose combination produced 9.8% weight loss.

Side effects include paresthesia (numbness and tingling, from topiramate), cognitive slowing, dry mouth, and constipation. It carries a teratogenicity risk (cleft palate in infants) requiring a risk evaluation and mitigation strategy (REMS) program and monthly pregnancy testing for women of childbearing potential. Contraindicated in glaucoma and hyperthyroidism.

Bupropion/Naltrexone (Contrave)

Approved in September 2014, Contrave combines bupropion (a norepinephrine/dopamine reuptake inhibitor) with naltrexone (an opioid receptor antagonist). The mechanistic rationale: bupropion activates hypothalamic POMC neurons that signal satiety; naltrexone blocks the autoinhibitory feedback loop on those same neurons via mu-opioid receptors, prolonging the anorectic signal. The COR-I phase 3 trial showed 5.4% weight loss from baseline at 56 weeks versus 1.3% for placebo. Modest compared to newer agents.

Nausea is the primary side effect (32% of patients in trials), usually transient. The bupropion component carries a boxed warning for neuropsychiatric symptoms and suicidality (inherited from its antidepressant labeling). Contraindicated with MAOIs and in patients with uncontrolled hypertension, seizure disorders, or eating disorders.

Orlistat — Peripheral Fat Blocker

Orlistat (Xenical prescription, Alli OTC) inhibits gastrointestinal lipases — enzymes that break down dietary fat for absorption. Approximately 30% of ingested fat passes undigested into the colon. At the highest studied dose of 120 mg three times daily with meals, orlistat produces about 2.9 kg more weight loss than placebo at 1 year, and modest improvements in cholesterol and blood pressure independent of weight loss (by blocking fat absorption directly).

The mechanism produces predictable side effects: fatty/oily stools, fecal urgency, oily spotting, and flatus with discharge. Adherence to a low-fat diet (<30% of calories from fat) is practically necessary to avoid these effects. Orlistat also impairs absorption of fat-soluble vitamins A, D, E, and K — supplementation is recommended. It is taken only when eating a meal containing fat, skipped for fat-free meals.

Liraglutide 3 mg (Saxenda)

Liraglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes (Victoza 1.2–1.8 mg). At the higher dose of 3 mg daily, approved for obesity in December 2014 (Saxenda), it produces centrally mediated appetite suppression and slows gastric emptying. The SCALE Obesity and Prediabetes trial showed a mean weight loss of 8.4% from baseline at 56 weeks versus 2.8% for placebo — a net 5.6 percentage point advantage.

• Route: daily subcutaneous injection, titrated up over 5 weeks to reach the 3 mg dose.
• Side effects: nausea (40%), vomiting, diarrhea, constipation; risk of pancreatitis (discontinue if suspected); contraindicated with personal or family history of medullary thyroid carcinoma.
• Weight regain: a 2022 follow-up study showed participants regained two-thirds of lost weight within one year of stopping liraglutide.

Semaglutide 2.4 mg (Wegovy) — The New Benchmark

Semaglutide (Wegovy), approved in June 2021, is also a GLP-1 receptor agonist but with a longer half-life (weekly dosing) and higher potency. The STEP 1 trial (1,961 adults) showed a mean weight loss of 14.9% from baseline at 68 weeks versus 2.4% for placebo — the largest effect size of any approved obesity medication at the time. Nearly 70% of participants lost ≥10% of body weight, and 32% lost ≥20%.

Weight Regain After Stopping

The weight-regain evidence is consistent across all agents. Biology fights back. Without ongoing medication or sustained behavioral change, approximately two-thirds of lost weight returns within 12 months of stopping. The SELECT cardiovascular outcomes trial with semaglutide (2023) demonstrated a 20% reduction in major adverse cardiovascular events in overweight adults with established cardiovascular disease — reframing obesity medication as cardiovascular prevention rather than purely cosmetic weight management. Insurance coverage nevertheless remains a major barrier for all these agents, with monthly costs ranging from $100 (orlistat generic) to over $1,300 (Wegovy) without coverage.

This article is for informational purposes only. Consult a qualified healthcare professional.